Amidst a backdrop of industry-wide hurdles like inflation, talent scarcities, and stringent regulatory landscapes, Nona Biosciences is showing great promise as an emerging global leader in biotechnology.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), a global biotech company focusing on the discovery and development of novel antibody therapeutics, today announces an antibody evaluation, option and license agreement with Ona Therapeutics ("Ona"), a Spanish biotech company specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer.